A2 Bio Announces Oral and Poster Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Presentations highlight selectivity of A2’s proprietary Tmod^TM CAR T therapies for solid tumors and ability to pre-select patients based on tumor mutations

A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced an oral presentation and two poster presentations of trial-in-progress data from their pre-screening (BASECAMP-1) and first-in-human Phase 1 study (EVEREST-1) at the 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA.

Oral presentation

BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials

Presenter: Diane Simeone, MD - NYU

Session: Rapid Oral Abstract-Clinical | Session 105b

Date and time: Friday, November 3; 12:15pm - 1:15pm PT

Location: Ground Level - Exhibit Hall C - San Diego Convention Center

Poster presentations

EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

Abstract: 634

Presenter: Salman Punekar, MD - NYU

Date and time: Saturday, November 4, 2023; 9am - 8:30pm PT

Location: Exhibit Halls A and B1 – San Diego Convention Center

BASECAMP-1: A master prescreening study to identify patients with high-risk or metastatic solid tumors with HLA loss of heterozygosity (LOH) in preparation for Tmod CAR T-cell therapy trials

Abstract: 636

Presenter: Diane Simeone, MD - NYU

Date and time: Saturday, November 4, 2023; 9am - 8:30pm PT

Location: Exhibit Halls A and B1 – San Diego Convention Center

About A2 Bio

A2 Biotherapeutics, Inc. (A2 Bio) is a clinical-stage biotech company developing first-in-class logic-gated cell therapies to address the high unmet need in cancers. A2 Bio has invented the proprietary Tmod™ cell therapy platform to tackle the fundamental challenge in solid tumor treatment—the ability of cancer medicines to distinguish between tumor and normal cells. For more information, please visit the company’s website at www.a2bio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231016124997/en/

A2 Bio announces oral and poster presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting